This long-running misrepresentation of sales gave ArthroCare the appearance of significant growth, and its stock price climbed—even as Baker lied to investors and analysts about ArthroCare’s relationships with its distributors.
This long-running misrepresentation of sales gave ArthroCare the appearance of significant growth, and its stock price climbed—even as Baker lied to investors and analysts about ArthroCare’s relationships with its distributors.